Oneness Biotech's FESPIXON® Cream Passes Initial Review for Inclusion in China's National Health Insurance

On the evening of the 7th, Oneness Biotech announced that its new drug for diabetic foot ulcers, FESPIXON® Cream, passed the initial formal review by China's National Healthcare Security Administration (NHSA) on that same day. This marks the first step towards securing inclusion in the national health insurance scheme for FESPIXON®.